• Something wrong with this record ?

One-Year Results of Fixed Aflibercept Treatment Regime in Type 3 Neovascularization

J. Ernest, K. Manethova, P. Kolar, L. Sobisek, R. Sacconi, G. Querques,

. 2020 ; 243 (1) : 58-65. [pub] 20190523

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20028675

PURPOSE: To evaluate the effect of intravitreal aflibercept injections in treatment-naive type 3 neovascularization using a fixed treatment regime during the first year of therapy. METHODS: Fourteen eyes of 14 patients diagnosed with type 3 neovascularization were studied. All patients were treated with intravitreal aflibercept injections using a fixed treatment regime of 3 consecutive monthly dosages followed by 2-month interval injections. Results were assessed after a 12-month follow-up period. Changes of best corrected visual acuity (BCVA), central retinal thickness (CRT), central macular volume (CMV), and retinal pigment epithelium (RPE) atrophy at fundus autofluorescence and infrared reflectance images were recorded and analyzed. RESULTS: BCVA improved from 60.3 ± 11.7 ETDRS letters at the baseline to 70.9 ± 10.3 ETDRS letters at 12-months follow-up (p = 0.036). Also, CRT and CMV statistically improved after the treatment (from 425 ± 117 to 308 ± 117 µm [p = 0.031] and from 9.52 ± 1.90 to 8.29 ± 0.95 mm3 [p = 0.073], respectively). In 4 patients, development and progression of RPE atrophy were observed, and it was associated with the presence of serous pigment epithelium detachment at the baseline. Furthermore, the development of a fibrotic lesion eccentric to the fovea was observed in 5 patients, without significant impairment of BCVA (p = 0.290). CONCLUSION: Intravitreal aflibercept administered in a fixed treatment regime during the first year of therapy may be effective for the improvement and stabilization of BCVA in eyes with type 3 neovascularization. However, RPE atrophy and subretinal/intraretinal fibrosis can develop during the treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028675
003      
CZ-PrNML
005      
20210114154656.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000499719 $2 doi
035    __
$a (PubMed)31121590
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Ernest, Jan $u Department of Ophthalmology, Military University Hospital Prague, Prague, Czechia. Axon Clinical Ltd., Clinical Research Centre, Prague, Czechia.
245    10
$a One-Year Results of Fixed Aflibercept Treatment Regime in Type 3 Neovascularization / $c J. Ernest, K. Manethova, P. Kolar, L. Sobisek, R. Sacconi, G. Querques,
520    9_
$a PURPOSE: To evaluate the effect of intravitreal aflibercept injections in treatment-naive type 3 neovascularization using a fixed treatment regime during the first year of therapy. METHODS: Fourteen eyes of 14 patients diagnosed with type 3 neovascularization were studied. All patients were treated with intravitreal aflibercept injections using a fixed treatment regime of 3 consecutive monthly dosages followed by 2-month interval injections. Results were assessed after a 12-month follow-up period. Changes of best corrected visual acuity (BCVA), central retinal thickness (CRT), central macular volume (CMV), and retinal pigment epithelium (RPE) atrophy at fundus autofluorescence and infrared reflectance images were recorded and analyzed. RESULTS: BCVA improved from 60.3 ± 11.7 ETDRS letters at the baseline to 70.9 ± 10.3 ETDRS letters at 12-months follow-up (p = 0.036). Also, CRT and CMV statistically improved after the treatment (from 425 ± 117 to 308 ± 117 µm [p = 0.031] and from 9.52 ± 1.90 to 8.29 ± 0.95 mm3 [p = 0.073], respectively). In 4 patients, development and progression of RPE atrophy were observed, and it was associated with the presence of serous pigment epithelium detachment at the baseline. Furthermore, the development of a fibrotic lesion eccentric to the fovea was observed in 5 patients, without significant impairment of BCVA (p = 0.290). CONCLUSION: Intravitreal aflibercept administered in a fixed treatment regime during the first year of therapy may be effective for the improvement and stabilization of BCVA in eyes with type 3 neovascularization. However, RPE atrophy and subretinal/intraretinal fibrosis can develop during the treatment.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a injekce intravitreální $7 D058449
650    _2
$a macula lutea $x patologie $7 D008266
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a receptory vaskulárního endoteliálního růstového faktoru $x aplikace a dávkování $x antagonisté a inhibitory $7 D040262
650    _2
$a rekombinantní fúzní proteiny $x aplikace a dávkování $7 D011993
650    _2
$a retinální pigmentový epitel $x patologie $7 D055213
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a optická koherentní tomografie $7 D041623
650    12
$a zraková ostrost $7 D014792
650    _2
$a vlhká makulární degenerace $x diagnóza $x farmakoterapie $7 D057135
655    _2
$a časopisecké články $7 D016428
700    1_
$a Manethova, Katerina $u Department of Ophthalmology, Military University Hospital Prague, Prague, Czechia. Axon Clinical Ltd., Clinical Research Centre, Prague, Czechia.
700    1_
$a Kolar, Petr $u Department of Ophthalmology, University Hospital Brno, Brno, Czechia.
700    1_
$a Sobisek, Lukas $u Department of Statistics and Probability, University of Economics in Prague, Prague, Czechia.
700    1_
$a Sacconi, Riccardo $u Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy.
700    1_
$a Querques, Giuseppe $u Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, giuseppe.querques@hotmail.it.
773    0_
$w MED00003619 $t Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde $x 1423-0267 $g Roč. 243, č. 1 (2020), s. 58-65
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31121590 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154653 $b ABA008
999    __
$a ok $b bmc $g 1609010 $s 1119855
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 243 $c 1 $d 58-65 $e 20190523 $i 1423-0267 $m Ophthalmologica $n Ophthalmologica $x MED00003619
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options